Sionna Therapeutics’ (SION) Buy Rating Reiterated at BTIG Research

BTIG Research reaffirmed their buy rating on shares of Sionna Therapeutics (NASDAQ:SION) in a research note released on Wednesday morning,Benzinga reports. The firm currently has a $58.00 target price on the stock.

Several other analysts also recently commented on the company. Wall Street Zen upgraded Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sionna Therapeutics in a report on Monday, December 29th. Lifesci Capital started coverage on Sionna Therapeutics in a research note on Tuesday, December 23rd. They issued an “outperform” rating and a $60.00 price objective for the company. Raymond James Financial reaffirmed a “strong-buy” rating and set a $53.00 target price on shares of Sionna Therapeutics in a research report on Monday, January 5th. Finally, Royal Bank Of Canada reissued an “underperform” rating and issued a $24.00 price target on shares of Sionna Therapeutics in a research report on Monday, December 1st. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $45.43.

Sionna Therapeutics Stock Up 0.4%

NASDAQ:SION opened at $39.02 on Wednesday. Sionna Therapeutics has a twelve month low of $7.26 and a twelve month high of $45.00. The company has a fifty day moving average of $40.76 and a 200-day moving average of $30.71. The firm has a market capitalization of $1.74 billion and a P/E ratio of -8.01.

Sionna Therapeutics (NASDAQ:SION) last issued its earnings results on Wednesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.06.

Insider Activity at Sionna Therapeutics

In related news, Director Peter A. Thompson sold 94,583 shares of the company’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $44.54, for a total transaction of $4,212,726.82. Following the completion of the sale, the director owned 3,610,376 shares in the company, valued at approximately $160,806,147.04. This represents a 2.55% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Michael Cloonan sold 99,800 shares of the firm’s stock in a transaction on Tuesday, October 21st. The shares were sold at an average price of $36.26, for a total value of $3,618,748.00. Following the transaction, the chief executive officer owned 547,343 shares in the company, valued at approximately $19,846,657.18. This trade represents a 15.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 1,071,548 shares of company stock valued at $42,687,226 over the last 90 days. Corporate insiders own 3.90% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in SION. Viking Global Investors LP grew its position in Sionna Therapeutics by 8.2% in the 2nd quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock worth $55,436,000 after purchasing an additional 242,427 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Sionna Therapeutics by 2.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 2,221,188 shares of the company’s stock worth $38,538,000 after buying an additional 51,589 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Sionna Therapeutics by 81.4% in the third quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock valued at $33,620,000 after acquiring an additional 512,803 shares in the last quarter. Braidwell LP purchased a new stake in shares of Sionna Therapeutics during the second quarter valued at approximately $18,770,000. Finally, Aberdeen Group plc lifted its holdings in Sionna Therapeutics by 27.4% during the second quarter. Aberdeen Group plc now owns 950,547 shares of the company’s stock worth $16,492,000 after acquiring an additional 204,583 shares during the period.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.